


AMENDMENTS TO THE CLAIMS:

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of the formula (I):



wherein X is OH or lower alkylsufonyloxy;

Ar is optionally substituted aryl or optionally substituted heteroaryl;

n is an integer of 1 to 4;

m is an integer of 0 to 1;

R^1 is hydrogen;

R^2 is OH or

R^1 and R^2 taken together may form a single bond;

excluding that

1) n is 2; m is 0; R^1 and R^2 taken together may form a single bond; and Ar is optionally substituted phenyl and

2) n is 3; m is 0; R^1 and R^2 taken together may form a single bond; and Ar is phenyl,

or a pharmaceutically acceptable salt or a solvate hydrate thereof.

2. (Currently Amended) A compound according to Claim 1 wherein n is 3 or 4, or a pharmaceutically acceptable salt, or a ~~solvate~~-hydrate thereof.

3. (Currently Amended) A compound according to Claim 1 wherein m is 1, or a pharmaceutically acceptable salt or a ~~solvate~~-hydrate thereof.

4. (Currently Amended) A compound according to Claim 1 wherein n is 3; m is 1; and Ar is optionally substituted phenyl, or a pharmaceutically acceptable salt or a ~~solvate~~-hydrate thereof.

5. (Currently Amended) A compound according to Claim 1 wherein n is 3; m is 1; R¹ is hydrogen; R² is OH; and Ar is optionally substituted phenyl, or a pharmaceutically acceptable salt or a ~~solvate~~-hydrate thereof.

6. (Currently Amended) A compound according to Claim 1 wherein n is 3; m is 1; R¹ and R² taken together may form a single bond; and Ar is optionally substituted phenyl, or a pharmaceutically acceptable salt, or a ~~solvate~~-hydrate thereof.

7. (Currently Amended) A compound according to Claim 1 wherein n is 3; m is 0; R¹ and R² taken together may form a single bond; and Ar is substituted phenyl, or a pharmaceutically acceptable salt, or a ~~solvate~~-hydrate thereof.

8. (Currently Amended) A compound according to Claim 1 wherein Ar is optionally substituted heteroaryl, or a pharmaceutically acceptable salt or a ~~solvate~~-hydrate thereof.

9. (Currently Amended) A compound according to Claim 1 wherein n is 3; m is 0; R¹ and R² taken together may form a single bond; and Ar is optionally substituted heteroaryl, or a pharmaceutically acceptable salt or a ~~solvate~~-hydrate thereof.

10. (Currently Amended) A pharmaceutical composition comprising a compound according to Claim 1 and at least one pharmaceutically acceptable carrier.

11. (Previously Presented) The pharmaceutical composition according to Claim 10 having NMDA receptor antagonistic activity.

12. (Previously Presented) The pharmaceutical composition according to Claim 11 having NR1/NR2B receptor antagonistic activity.

13. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 which is an analgesic or a medicament for treating migraine, stroke, head injury, Alzheimer's disease, Parkinson's disease, or tinnitus.

14. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 which is an analgesic.

15. (Previously Presented) A method for alleviating pain or treating migraine, stroke, head injury, Alzheimer's disease, Parkinson's disease, or tinnitus comprising administering a compound according to Claim 1.

16. (Previously Presented) A method for alleviating pain comprising administering a compound according to Claim 1.

17. (Previously Presented) A method for manufacturing an analgesic or a medicament for treating migraine, stroke, head injury, Alzheimer's disease, Parkinson's disease, or tinnitus;

the method comprises using a compound according to claim 1 to manufacture the analgesic or medicament.

18. (Previously Presented) A method for manufacturing an analgesic;

the method comprising using a compound according to claim 1 to manufacture the analgesic.